Firefly Neuroscience, Inc. (AIFF)
NASDAQ: AIFF · Real-Time Price · USD
2.030
-0.320 (-13.62%)
At close: Oct 22, 2025, 4:00 PM EDT
2.038
+0.008 (0.41%)
After-hours: Oct 22, 2025, 7:04 PM EDT
Firefly Neuroscience Employees
Firefly Neuroscience had 13 employees as of December 31, 2024.
Employees
13
Change
n/a
Growth
n/a
Revenue / Employee
$32,923
Profits / Employee
-$2,095,923
Market Cap
27.30M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Microsoft | 228,000 |
| Apple | 164,000 |
| Oracle | 162,000 |
| SAP SE | 109,973 |
| Cisco Systems | 86,200 |
| Taiwan Semiconductor Manufacturing Company | 83,825 |
| ASML Holding | 44,027 |
| Broadcom | 37,000 |
AIFF News
- 6 weeks ago - Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America - GlobeNewsWire
- 2 months ago - Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR' Platform - GlobeNewsWire
- 3 months ago - Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research - GlobeNewsWire
- 4 months ago - Firefly Neuroscience to be Added to the Russell Microcap® Index - GlobeNewsWire
- 4 months ago - Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer's Patients - GlobeNewsWire
- 6 months ago - Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc. - GlobeNewsWire
- 6 months ago - Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc. - GlobeNewsWire
- 8 months ago - Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01 - Newsfile Corp